| Biotechnology Industry | Healthcare Sector | Mr. Peter Halling CEO | XCSE Exchange | - ISIN |
| Denmark Country | 2,753 Employees | - Last Dividend | 28 Mar 2022 Last Split | - IPO Date |
ALK-Abelló A/S is a leading allergy solutions company with a global footprint, catering to the needs of allergy sufferers in Europe, North America, and other international markets. Founded in 1923 and based in Hørsholm, Denmark, ALK-Abelló A/S focuses on developing innovative products and solutions for the treatment and management of allergic rhinitis and allergic asthma. The company's approach to allergy treatment encompasses a comprehensive portfolio of allergy immunotherapy (AIT) products available in various forms such as injections, sublingual drops, and tablets. Furthermore, ALK-Abelló A/S extends its commitment to allergy care by offering consumer healthcare solutions, diagnostic allergy testing services, and emergency treatments for acute allergic reactions, with a focus on integrating digital platforms to enhance patient engagement and care.
These flagship products by ALK-Abelló provide targeted treatment for various allergies including grass, ragweed, house dust mite, Japanese cedar, tree, and food allergies through sublingual tablets, enhancing the quality of life for allergy sufferers by reducing symptoms and dependency on symptomatic medications.
ALK-Abelló's allergy immunotherapy products are designed to treat the underlying cause of allergic reactions, offering a long-term solution for managing allergic rhinitis and allergic asthma. By exposing the patient to gradually increasing doses of the allergen, these treatments aim to desensitize the body, reducing the severity of allergic responses.
Incorporating a Digital eco-system, ALK-Abelló connects with allergy sufferers throughout their disease journey, offering tools, e-commerce offerings, and support systems. This platform provides guidance and relief, and smoothens the path to allergy immunotherapy treatment, optimizing patient care and engagement.
To accurately diagnose allergies, ALK-Abelló offers comprehensive testing services which include skin prick tests and blood tests. These diagnostic tools are crucial for identifying specific allergens responsible for allergic reactions, enabling personalized and effective treatment plans.
For the management of life-threatening allergic emergencies such as anaphylaxis, ALK-Abelló provides adrenaline auto-injectors. These emergency treatments are essential for prompt response to severe allergic reactions, significantly reducing the risk of complications.
Through its partnership with Torii Pharmaceutical Co., Ltd., ALK-Abelló is involved in the development, marketing, and distribution of allergy immunotherapy tablets for the treatment of grass pollen allergy, demonstrating its commitment to expanding its therapeutic offerings and accessibility of its treatments in different markets.